4 unchanged sentences
District Court for the Northern District of California against our company and certain of our officers and current and former members of our board of directors, Bergman v.
−Removed: Caribou Biosciences, Inc., et al.
−Removed: , Case Number 23-cv-01742 (“Bergman Case”).
−Removed: The Bergman complaint challenged disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act.
−Removed: On September 18, 2023, plaintiffs filed an amended complaint adding the IPO underwriters as defendants and making substantially the same allegations as the original complaint.
+Added: Caribou Biosciences, Inc., et al., case number 3:23-cv-01742 (“Bergman Case”).
+Added: The Bergman Case complaint challenged disclosures regarding our company’s business, operations, and prospects, specifically with respect to the alleged durability of CB-010’s therapeutic effect and the product candidate’s clinical and commercial prospects, in alleged violation of Sections 11 and 15 of the Securities Act of 1933, as amended (“Securities Act”), and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”).On September 18, 2023, plaintiffs filed an amended complaint adding the IPO underwriters as defendants and making substantially the same allegations as the original complaint.
On November 14, 2023, we filed a motion to dismiss the amended complaint for failure to state a claim.
1 unchanged sentence
On April 22, 2024, we reached an agreement in principle with plaintiffs to settle the Bergman Case for $3.9 million in exchange for a full release of the putative class’s claims against us and all our current and former officers, current and former members of our board of directors, the IPO underwriters, and the other named defendant.
−Removed: The parties filed a settlement agreement with the court on June 26, 2024, and, on October 15, 2024, the court issued an order preliminarily approving the settlement and setting a final settlement approval hearing for February 18, 2025.
+Added: On February 18, 2025, the court issued an order granting final approval of the settlement.
+Added: On December 24, 2024, a putative class action lawsuit was filed in the U.S.
+Added: District Court for the Northern District of California against our company and certain of our current and former officers, Saylor v.
+Added: Caribou Biosciences, Inc., et al., case number 3:24-cv-09413 (“Saylor Case”).
+Added: The alleged class period is July 14, 2023, to July 16, 2024.
+Added: The Saylor Case complaint challenges disclosures regarding our business, operations, and prospects, specifically with respect to the alleged safety, efficacy, and durability of CB-010, CB-010’s clinical results and commercial prospects, and our financial statements, in alleged violation of Sections 10(b) and 20(a) of the Exchange Act.
+Added: On April 15, 2025, the lead plaintiff filed a motion to voluntarily dismiss the lawsuit and, on April 27, 2025, the court granted the motion, dismissing the lawsuit without prejudice.
+Added: On March 3, 2025, a shareholder derivative complaint was filed in the U.S.
+Added: District Court for the Northern District of California against our directors and certain of our current and former officers, Moisio, derivatively on behalf of Caribou Biosciences, Inc.
+Added: Haurwitz, et al, case number 4:25-cv-02199 (“First Derivative Case”), alleging, among other things, that the named directors and officers breached their fiduciary duties by causing our company to make the disclosures being challenged in the Saylor Case and seeking unspecified monetary damages from our company as well as that we make certain changes to our corporate governance.
+Added: On March 11, 2025, a second shareholder derivative complaint was filed in the U.S.
+Added: District Court for the Northern District of California against the same defendants as in the First Derivative Case, Allen, derivatively on behalf of Caribou Biosciences, Inc.
+Added: Braunstein, et al.
+Added: , case number 4:25-cv-02463 (“Second Derivative Case”), with the same allegations.
+Added: On April 1, 2025, the First Derivative Case and the Second Derivative Case were deemed related and assigned to the same judge and, on April 7, 2025, the First Derivative Case and the Second Derivative Case were consolidated into a single action, In re Caribou Biosciences, Inc.
+Added: Derivative Litigation , lead case number 4:25-cv-02199 (the “Consolidated Derivative Action”).
+Added: The Consolidated Derivative Action is at the preliminary stage of the proceedings.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.